Camptocormia as the presenting symptom in sporadic late onset nemaline myopathy: a case report

Matthias Türk, Armin M. Nagel, [...], and Rolf Schröder

Abstract

Background
Camptocormia has been reported in a plethora of diseases comprising disorders of the central nervous system, the peripheral nervous system, and the neuromuscular junction as well as hereditary and acquired myopathies. In sporadic late onset nemaline myopathy concomitant axial myopathy is common, but reports about camptocormia as the only presenting symptom in this condition are very rare. Notably, sporadic late onset nemaline myopathy is a potentially treatable condition in particular when associated with monoclonal gammopathy of unknown significance, HIV or rheumatological disorders.

Case presentation
We report the case of a 62-year-old female patient, who presented with slowly progressive camptocormia. Comprehensive work-up including neurological work-up, laboratory tests, MR-imaging, muscle biopsy and genetic testing led to the diagnosis of sporadic late onset nemaline myopathy.

Conclusions
Our case report highlights that sporadic late onset nemaline myopathy has to be considered in patients presenting with isolated camptocormia and comprehensive work-up of camptocormia is mandatory to ascertain the individual diagnosis, especially in consideration of treatable conditions.

Keywords: Camptocormia, Axial myopathy, Muscle biopsy, Nemaline rods, Sporadic late onset nemaline myopathy, SLONM

Background
Camptocormia is characterized by involuntary forward flexion of the thoracolumbar spine. In contrast to spinal deformities due to skeletal disorders, forward flexion in this condition typically increases in upright and resolves in supine position [1]. Camptocormia has been reported in a plethora of diseases comprising disorders of the central nervous system (i.a. Parkinson’s disease, dystonias, psychiatric/psychogenic disorders), the peripheral nervous system (i.a. amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy), and the neuromuscular junction (myasthenia gravis) as well as hereditary (i.a. congenital myopathies, central-core disease, mitochondrial myopathy, acid maltase deficiency, phosphorylase deficiency, fazio-scalpulo-humeral muscle dystrophy, myotonic dystrophy type I/II, dysferlinopathy, calpainopathy, myofibrillar myopathies) and acquired myopathies (inflammatory myopathies (polymyositis; dermatomyositis; inclusion body myositis), amyloid myopathy, hypothyroid myopathy, toxic myopathy) [1–6]. In patients with primary myopathy, camptocormia is due to myogenic dysfunction and weakness affecting the thoracolumbar paraspinal/axial muscle groups. Whereas the manifestation of camptocormia is often preceded by weakness of extra-axial muscles, data on camptocormia as the only presenting symptom in primary myopathies and in particular in sporadic late onset nemaline myopathy (SLONM) is scarce [3, 7–10].

Case presentation
We report the case of a 62-year-old female patient of European origin, who presented with slowly progressive camptocormia. Her progressive inability to walk upright started at the age of 52 years and was accompanied by generalized myalgias, which were independent of exertion. Her family history was negative for neurological and neuromuscular disorders and neurological examination at age 60 revealed isolated axial muscle weakness resulting in camptocormia (Fig. 1a). During 2 years follow-up, camptocormia slightly progressed and very mild facial weakness and mild weakness of pelvic-girdle muscles developed. There were no signs of movement disorder, myasthenia or cardiopulmonary involvement. Laboratory tests, including standard parameters, creatine kinase (70 U/l), thyroid-stimulating hormone, routine rheumatologic tests, protein electrophoresis and immunofixation of serum and urine were within normal limits. HIV-testing was negative. Needle electromyography of the right vastus lateralis muscle showed some muscle unit action potentials with increased amplitudes, but was otherwise normal. Whole body 3 T-MR-imaging revealed marked fatty atrophy of the lumbar and thoracic paraspinal muscles in T1-weighted sequences (Fig. 1b) without signs of active myositis in STIR-sequences (data not shown). Apart from a moderate bilateral fatty atrophy of the antero-lateral part of the gluteus medius muscles and less marked of the gluteus minimus muscles, MR-imaging of shoulder- and pelvic-girdle- as well as arm- and leg-muscles was regular (Fig. 1b). Light and electron microscopy analysis of a diagnostic muscle biopsy from the left vastus lateralis muscle showed a myopathic pattern with nemaline rods (Fig. 1c/d) in about 4% of the muscle fibers along with some lobulated fibers. In addition, type-I- and type-II-fiber-grouping consistent with a mild chronic neurogenic pattern was noted. Next-generation sequencing did not show any mutations in genes associated with hereditary nemaline myopathy (α-tropomyosin 3; Nebulin; α-Actin;
β-tropomyosin; Troponin T1; KBTBD13; Cofilin-2; KLHL40; KLHL41; LMOD3; MYPN; Ryanodine receptor 1) or any other myopathy-associated genes.

Discussion and conclusions

Camptocormia as the presenting symptom has been reported in a wide variety of primary myopathies including inflammatory myopathies, amyloid myopathy, myotonic dystrophy, muscular dystrophies (FSHD1; dysferlinopathy, symptomatic carrier of dystrophinopathy, calpainopathy), metabolic myopathies (McArdle; Pompe's disease), mitochondrial myopathies and toxic myopathy [3, 4].

In the reported patient with initially isolated camptocormia, our diagnostic work-up led to the diagnosis of sporadic late onset nemaline myopathy, which is defined as a late-onset and subacutely evolving muscle disorder. Schnitzler et al. recently published a systemic overview comprising a large cohort of 76 patients with SLONM, excluding patients with HIV infection [11]. In this analysis, the most typical clinical manifestations of SLONM were weakness and atrophy of proximal upper limb muscle groups followed by proximal lower limbs weakness. Axial weakness was reported in 68% of these patients. Less frequent symptoms were facial weakness, dyspnea, dysphagia, distal weakness, ophthalmoplegias, ptosis, myalgias and cramps. A very recent monocentric and retrospective case series by Naddaf et al. comprising 28 SLONM-patients reported axial weakness (i.e. head drop, camptocormia or general core weakness) as first noted symptom and as predominantly finding at presentation in 39 and 36% of all analyzed patients, respectively. In 47% of the reported patients, camptocormia was one of the presenting symptoms [12]. While axial weakness and camptocormia is a common feature, camptocormia as the only presenting symptom has been reported just in singular SLONM-patients [3, 8–10].

Though SLONM is rare, it is potentially a treatable condition. Patients with SLONM associated with HIV-infection or rheumatological diseases often show good clinical response to immunosuppressive therapy [11]. In SLONM patients without HIV-infection or rheumatological diseases therapy is still a matter of debate. Until recently, therapeutic interventions mainly focused on SLONM-patients with MGUS since those were assumed to have a more rapid progression and a very poor prognosis mainly due to respiratory failure [11, 13]. MGUS was detected in about half of the affected patients, analyzed in the study by Schnitzler et al. [11] In this subgroup of SLONM-patients, symptoms improved in several cases after immunosuppressive or -modulating therapy and especially after therapy with high-dose melphalan followed by autologous peripheral blood stem cell transplantation [11, 14, 15]. Interestingly, Naddaf et al. reported no difference in overall survival (92% in 5 years; 68% in 10 years) between SLONM-patients with or without MGUS. Notably, in their cohort all but one SLONM-patient (without MGUS) received immunotherapy. Based on their data, they recommend treatment with intravenous immunoglobulins as first line therapy in SLONM-patients irrespective of the presence of MGUS [12].

Regular check-ups including physical examination with special attention to cardiac and pulmonary testing are mandatory in SLONM-patients. Diagnostic work-up must repetitively address MGUS, HIV-infection [16] and rheumatological disorders [17, 18]. All of which were excluded in our patient by repeated laboratory testing and therapy was originally restricted to supportive care comprising physiotherapy and the use of nordic walking poles. However, treatment with intravenous immunoglobulins is reconsidered in our patient.

Whole body muscle MRI is a reliable diagnostic tool for detecting myopathy in patients with camptocormia and might further help to choose the site for muscle biopsy [6]. In our case, clinical diagnosis of camptocormia due to myopathy was supported by the MR-imaging findings which revealed a marked fatty atrophy almost exclusively affecting the lumbar and thoracic paraspinal muscles. Nevertheless, histopathological findings of nemaline myopathy were shown in a muscle biopsy from the vastus lateralis muscle. In this context, choosing the suitable site for biopsy in isolated axial myopathy is still a matter of debate, since normative findings for paraspinal muscle biopsy are lacking [5]. Noteworthy, deltoid muscle biopsy was shown to be able to detect an underlying myopathy in 35% of patients with isolated camptocormia [19] and apart from paraspinal muscles deltoid or vastus muscles might therefore be a possible site for muscle biopsy in these patients.

Our case report highlights that myopathy and in particular SLONM has to be considered in all patients with isolated camptocormia. SLONM should especially be suspected when camptocormica is combined with MGUS, HIV or rheumatological disease [12]. In all patients with camptocormia of unknown etiology, comprehensive work-up including muscle MRI and muscle biopsy is mandatory to ascertain the individual diagnosis, especially in consideration of treatable conditions.

Acknowledgements
Not Applicable.

**Authors’ contributions**

MT conceived the study, performed clinical and histological examinations, reviewed all data, prepared the figures, and wrote the manuscript. AMN and FR performed and analyzed the MR-imaging study and revised the manuscript for important intellectual content. USS performed the EM-analysis and revised the manuscript for important intellectual content. CTT performed genetic analysis and revised the manuscript for important intellectual content. MW conceived the study, performed clinical examinations and revised the manuscript for important intellectual content. RS conceived the study, performed histological examinations, reviewed all data, and wrote the manuscript. All authors read and approved the final manuscript.

**Abbreviations**

- HIV Human immunodeficiency virus
- MGUS Monoclonal gammopathy of undetermined significance
- SLONM Sporadic late onset nemaline myopathy

**Funding**

We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding programme Open Access Publishing.

**Availability of data and materials**

Data are contained within the manuscript.

**Ethics approval and consent to participate**

Whole body 3 T-MR-imaging study was approved by the ethics committee of the Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Germany (Ethics vote Nr. 342_16 B). Written informed consent was obtained from the patient for the MRI-investigation and the diagnostic muscle biopsy.

**Consent for publication**

Written informed consent for publication of the clinical details and clinical images was obtained from the patient.

**Competing interests**

The authors declare that they have no competing interests.

**Footnotes**

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Contributor Information**

Matthias Türk, Phone: +49 9131 85 46896, Email: Matthias.Tuerk@uk-erlangen.de.

Armin M. Nagel, Email: Armin.Nagel@uk-erlangen.de.

Frank Roemer, Email: Frank.Roemer@uk-erlangen.de.

Ursula Schlöter-Schrehardt, Email: Ursula.Schloetzer-Schrehardt@uk-erlangen.de.

Christian T. Thiel, Email: Christian.Thiel@uk-erlangen.de.

Martin Winterholler, Email: Martin.Winterholler@Sana.de.

Rolf Schröder, Email: Rolf.Schroeder@uk-erlangen.de.
Article information

BMC Musculoskelet Disord. 2019; 20: 553.
Published online 2019 Nov 20. doi: 10.1186/s12891-019-2942-0
PMCID: PMC6886766
PMID: 31747907

Matthias Türk,1 Armin M. Nagel,2 Frank Roemer,3 Ursula Schlüter-Schrehardt,4 Christian T. Thiel,5 Martin Winterholler,6 and Rolf Schröder7

1Department of Neurology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
2Institute of Radiology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Maximiliansplatz 3, 91054 Erlangen, Germany
3Institute of Radiology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Maximiliansplatz 3, 91054 Erlangen, Germany
4Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
5Institute of Human Genetics, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054 Erlangen, Germany
6Department of Neurology, Sana-Krankenhaus Rummelsberg, Rummelsberg 71, 90582 Schwarzenbruck, Germany
7Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany

Matthias Türk, Phone: +49 9131 85 46896, Email: Matthias.Tuerk@uk-erlangen.de.

Contributor information.

© Corresponding author.

Received 2019 Feb 5; Accepted 2019 Nov 12.

Copyright © The Author(s), 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Articles from BMC Musculoskeletal Disorders are provided here courtesy of BioMed Central

References

1. Finsterer J, Strobl W. Presentation, etiology, diagnosis, and management of camptocormia. Eur Neurol. 2010;64(1):1–8. doi: 10.1159/000314897. [PubMed] [CrossRef] [Google Scholar]

2. Umapathi T, Chaudhry V, Cornblath D, Drachman D, Griffin J, Kuncl R. Head drop and camptocormia. J Neurol Neurosurg Psychiatry. 2002;73(1):1–7. doi: 10.1136/jnnp.73.1.1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Ghosh PS, Milone M. Camptocormia as presenting manifestation of a spectrum of myopathic disorders. Muscle Nerve. 2015;52(6):1008–1012. doi: 10.1002/mus.24689. [PubMed] [CrossRef] [Google Scholar]

4. London F, Thevenon A, Levisse C, Cassin F, Tard C. Camptocormia and myalgia as the revealing symptoms of a drug-induced myopathy related to chronic orlistat intake: a case report. Acta Neurol Belg. 2017; Epub 2017/03/18. [PubMed]

5. Witting N, Andersen LG, Vissing J. Axial myopathy: an overlooked feature of muscle diseases. Brain. 2016;139(Pt 1):13–22. doi: 10.1093/brain/awv332. [PubMed] [CrossRef] [Google Scholar]

6. Ohana M, Durand MC, Marty C, Lazaroth JP, Maisonobe T, Mompoint D, et al. Whole-body muscle MRI to detect myopathies in non-extrapyramidal bent spine syndrome. Skelet Radiol. 2014;43(8):1113–1122. doi: 10.1007/s00256-014-1909-3. [PubMed] [CrossRef] [Google Scholar]

7. Laroche M, Cintas P. Bent spine syndrome (camptocormia): a retrospective study of 63 patients. Joint Bone Spine. 2010;77(6):593–596. doi: 10.1016/j.jbspin.2010.05.012. [PubMed] [CrossRef] [Google Scholar]

8. Kemta Lekpa F, Chevalier X, Dubourg O, Dimitri D. Isolated camptocormia revealing sporadic late onset nemaline myopathy. Presse Med. 2013;42(7–8):1142–1144. doi: 10.1016/j.lpm.2012.11.007. [PubMed] [CrossRef] [Google Scholar]

9. Carpenter S, Karpati G. Adult onset nemaline myopathy. In: Pathology of skeletal muscle. 2nd ed: Oxford University Press; 2001. p. 474.

10. Ozer F, Ozurtak O, Meral H, Serdaroglu P, Yayla V. Camptocormia in a patient with Parkinson disease and a myopathy with nemaline rods. Am J Phys Med Rehabil. 2007;86(1):3–6. doi: 10.1097/PHM.0b013e31802b88bde. [PubMed] [CrossRef] [Google Scholar]
11. Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, Stenzel W, Rushing EJ, Van Damme P, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis. 2017;12(1):86. doi: 10.1186/s13023-017-0640-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Naddaf E, Milone M, Kansagra A, Buadi F, Kourelis T. Sporadic late-onset nemaline myopathy: clinical spectrum, survival, and treatment outcomes. Neurology. 2019;93(3):e298–e305. doi: 10.1212/WNL.0000000000007777. [PubMed] [CrossRef] [Google Scholar]

13. Chahin N, Selcen D, Engel AG. Sporadic late onset nemaline myopathy. Neurology. 2005;65(8):1158–1164. doi: 10.1212/01.wnl.0000180362.90078.dc. [PubMed] [CrossRef] [Google Scholar]

14. Voermans NC, Benveniste O, Minnema MC, Lokhorst H, Lammens M, Meersseman W, et al. Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT. Neurology. 2014;83(23):2133–2139. doi: 10.1212/WNL.0000000000001047. [PubMed] [CrossRef] [Google Scholar]

15. Mizuno Y, Mori-Yoshimura M, Okamoto T, Oya Y, Nishino I, Murata M. Two cases of sporadic late onset nemaline myopathy effectively treated with immunotherapy. Rinsho Shinkeigaku. 2016;56(9):605–611. doi: 10.5692/cclinicalneurol.cn-000893. [PubMed] [CrossRef] [Google Scholar]

16. Silva AMS, Mendonca RH, Moreno CAM, Estephan EP, Helito PVP, Carvalho MS, et al. Clinical, histological and radiological responses to methylprednisolone in HIV-associated rod myopathy. Neuromuscul Disord. 2017;27(8):756–759. doi: 10.1016/j.nmd.2017.05.008. [PubMed] [CrossRef] [Google Scholar]

17. Suzuki M, Shimizu Y, Takeuchi M, Kobayashi M, Iwata M, Uchiyama S. Sporadic late-onset nemaline myopathy in a patient with primary Sjogren's syndrome. J Neurol. 2012;259(2):358–360. doi: 10.1007/s00415-011-6160-4. [PubMed] [CrossRef] [Google Scholar]

18. Dimitri D, Dubourg O. Sporadic late-onset nemaline myopathy in a patient with systemic lupus erythematosus. J Neurol. 2013;260(12):3171–3173. doi: 10.1007/s00415-013-7168-8. [PubMed] [CrossRef] [Google Scholar]

19. Chanson JB, Lannes B, Echaniz-Laguna A. Is deltoid muscle biopsy useful in isolated camptocormia? A prospective study. Eur J Neurol. 2016;23(6):1086–1092. doi: 10.1111/ene.12989. [PubMed] [CrossRef] [Google Scholar]